Anti-hyperglycemic drugs and lifestyle changes are highlighted as key strategies to prevent pump dysfunction and safeguard cardiovascular health in patients with diabetic cardiomyopathy.
Do anti-hyperglycemic drugs and lifestyle changes prevent pump dysfunction and improve cardiovascular health in patients with type 2 diabetes and diabetic cardiomyopathy?
This review provides a comprehensive overview of diabetic cardiomyopathy and the role of modern anti-hyperglycemic therapies in preventing heart failure in patients with type 2 diabetes.
Cardiovascular diseases are the leading cause of death in people with diabetes. Diabetic cardiomyopathy (DC) is an important complication of diabetes and represents a distinct subtype of heart failure that occurs in absence of cardiovascular diseases. Chronic hyperglycemia and hyperinsulinemia along with insulin resistance and inflammatory milieu are the main mechanisms involved in the pathophysiology of DC. Changes in lifestyle favoring healthy dietary patterns and physical activity, combined with more innovative anti-diabetes therapies, are the current treatment strategies to safeguard the cardiovascular system. This review aims at providing an updated comprehensive overview of clinical, pathogenetic, and molecular aspects of DC, with a focus on the effects of anti-hyperglycemic drugs on the prevention of pump dysfunction and consequently on cardiovascular health in type 2 diabetes.
Longo et al. (Tue,) conducted a review in Diabetic cardiomyopathy. Anti-hyperglycemic drugs and lifestyle changes was evaluated. Anti-hyperglycemic drugs and lifestyle changes are highlighted as key strategies to prevent pump dysfunction and safeguard cardiovascular health in patients with diabetic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: